Microwave ablation or plus monochemotherapy in elderly advanced non-small-cell lung cancer patients

References

• Chen W, Sun K, Zheng R, et al. Cancer incidence and mortality in China, 2014. Chin J Cancer Res. 2018;30(1):1–12.
   PubMed Web of Science ®Google Scholar
• Travis WD, Brambilla E, Burke AP, et al. Classification of tumours of the lung, pleura, thymus and heart. Lyon (France): International Agency for Research on Cancer; 2015.
   Google Scholar
• Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review, 1975–2010. Bethesda (MD): National Cancer Institute; 2013.
   Google Scholar
• Weir HK, Thun MJ, Hankey BF, et al. Lung cancer in the elderly. Eur J Cancer. 1997; 33:2313–2314.
   PubMedGoogle Scholar
• Weir HK, Thun MJ, Hankey BF, et al. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst. 2003;95(17):1276–1299.
   PubMed Web of Science ®Google Scholar
• Russo A, Rizzo S, Fulfaro F, et al. Gemcitabine-based doublets versus single-agent therapy for elderly patients with advanced non-small cell lung cancer: a literature-based meta-analysis. Cancer. 2009;115(9):1924–1931.
   PubMed Web of Science ®Google Scholar
• Qi WX, Tang LN, He AN, et al. Doublet versus single cytotoxic agent as first-line treatment for elderly patients with advanced non-small-cell lung cancer: a systematic review and meta-analysis. Lung. 2012;190:477–485.
   PubMed Web of Science ®Google Scholar
• Wang S, Wang Q, Tian J, et al. Meta-analysis comparing doublet and single cytotoxic agent therapy as first-line treatment in elderly patients with advanced non-small-cell lung cancer. J Int Med Res. 2015;43(6):727–737.
   PubMed Web of Science ®Google Scholar
• Wolf FJ, Grand DJ, Machan JT, et al. Microwave ablation of lung malignancies: effectiveness, CT findings, and safety in 50 patients. Radiology. 2008;247(3):871–879.
   PubMed Web of Science ®Google Scholar
• Mouli SK, Kurilova I, Sofocleous CT, et al. The role of percutaneous image-guided thermal ablation for the treatment of pulmonary malignancies. AJR Am J Roentgenol. 2017;209(4):740–751.
   PubMed Web of Science ®Google Scholar
• Sharma A, Abtin F, Shepard JA. Image-guided ablative therapies for lung cancer. Radiol Clin North Am. 2012;50(5):975–999.
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu B, Cao P, et al. Comparison between computed tomography-guided percutaneous microwave ablation and thoracoscopic lobectomy for stage I non-small cell lung cancer. Thorac Cancer. 2018;9(11):1376–1382.
   PubMed Web of Science ®Google Scholar
• Narsule CK, Sridhar P, Nair D, et al. Percutaneous thermal ablation for stage IA non-small cell lung cancer: long-term follow-up. J Thorac Dis. 2017;9(10):4039–4045.
   PubMed Web of Science ®Google Scholar
• Yang X, Ye X, Huang G, et al. Repeated percutaneous microwave ablation for local recurrence of inoperable Stage I nonsmall cell lung cancer. J Can Res Ther. 2017;13:683–688.
   PubMed Web of Science ®Google Scholar
• Han X, Yang X, Ye X, et al. Computed tomography-guided percutaneous microwave ablation of patients 75 years of age and older with early-stage nonsmall cell lung cancer. Indian J Cancer. 2015;52 (Suppl 2):e56–e60.
   PubMed Web of Science ®Google Scholar
• Yang X, Ye X, Lin Z, Jin Y, Zhang K, Dong Y, et al. Computed tomography-guided percutaneous microwave ablation for treatment of peripheral ground-glass opacity-lung adenocarcinoma: a pilot study. J Cancer Res Ther. 2018;14(4):764–771.
   PubMed Web of Science ®Google Scholar
• Yang X, Ye X, Zheng A, et al. Percutaneous microwave ablation of stage I medically inoperable non-small cell lung cancer: clinical evaluation of 47 cases. J Surg Oncol. 2014;110(6):758–763.
   PubMed Web of Science ®Google Scholar
• Sun YH, Song PY, Guo Y, et al. Effects of microwave ablation or its combination with whole-body chemotherapy on serum vascular endothelial growth factor levels in patients with stage IIIB/IV NSCLC. Genet Mol Res. 2015;14(3):10015–10025.
   PubMed Web of Science ®Google Scholar
• Yang X, Ye X, Huang G, Han X, Wang J, Li W, et al. Repeated percutaneous microwave ablation for local recurrence of inoperable stage I non small cell lung cancer. J Cancer Res Ther. 2017;13(4):683–688.
   PubMed Web of Science ®Google Scholar
• Wei Z, Ye X, Yang X, et al. Microwave ablation in combination with chemotherapy for the treatment of advanced non-small cell lung cancer. Cardiovasc Intervent Radiol. 2015;38(1):135–142.
   PubMed Web of Science ®Google Scholar
• Wei Z, Ye X, Yang X, et al. Microwave ablation plus chemotherapy improved progression-free survival of advanced non-small cell lung cancer compared to chemotherapy alone. Med Oncol. 2015;32(2):464–471.
   PubMed Web of Science ®Google Scholar
• Wei Z, Ye X, Geng D, et al. Microwave ablation plus chemotherapy versus chemotherapy in advanced non-small cell lung cancer: a prospective, randomized, control, phase III clinical trial. J Clin Oncol. 2017;35(15_suppl):9048. Abstract.
   Google Scholar
• Ahmed M, Solbiati L, Brace CL, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria–a 10-year update. Radiology. 2014;273(1):241–260.
   PubMed Web of Science ®Google Scholar
• Ye X, Fan W, Wang H, et al. Expert consensus workshop report: Guidelines for thermal ablation of primary and metastatic lung tumors (2018 edition). J Can Res Ther. 2018;14(4):730–744.
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247.
   PubMed Web of Science ®Google Scholar
• Gridelli C, Perrone F, Gallo C, et al. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst. 1999;91:66–72.
   PubMedGoogle Scholar
• Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the multicenter Italian lung cancer in the elderly study (MILES) phase III randomized trial. J Natl Cancer Inst. 2003;95(5):362–372.
   PubMed Web of Science ®Google Scholar
• Quoix E, Zalcman G, Oster JP, et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet. 2011;378(9796):1079–1088.
   PubMed Web of Science ®Google Scholar
• Kudoh S, Takeda K, Nakagawa K, et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non–small-cell lung cancer: Results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol. 2006;24(22):3657–3663.
   PubMed Web of Science ®Google Scholar
• Frasci G, Lorusso V, Panza N, et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol. 2000;18(13):2529–2536.
   PubMed Web of Science ®Google Scholar
• Abe T, Takeda K, Ohe Y, et al. Randomized phase III trial comparing weekly docetaxel plus cisplatin versus docetaxel monotherapy every 3 weeks in elderly patients with advanced non–small-cell lung cancer: the Intergroup trial JCOG0803/WJOG4307L. J Clin Oncol. 2015;33(6):575–581.
   PubMed Web of Science ®Google Scholar
• Kong G, Anyarambhatla G, Petros WP, et al. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release. Cancer Res. 2000;60(24):6950–6957.
   PubMed Web of Science ®Google Scholar
• Goldberg SN, Saldinger PF, Gazelle GS, et al. Percutaneous tumor ablation: increased necrosis with combined radio-frequency ablation and intratumoral doxorubicin injection in a rat breast tumor model. Radiology. 2001;220(2):420–427.
   PubMed Web of Science ®Google Scholar
• Goldberg SN, Girnan GD, Lukyanov AN, et al. Percutaneous tumor ablation: increased necrosis with combined radio-frequency ablation and intravenous liposomal doxorubicin in a rat breast tumor model. Radiology. 2002;222(3):797–804.
   PubMed Web of Science ®Google Scholar
• Goldberg SN, Kamel IR, Kruskal JB, et al. Radiofrequency ablation of hepatic tumors: increased tumor destruction with adjuvant liposomal doxorubicin therapy. AJR Am J Roentgenol. 2002;179(1):93–101.
   PubMed Web of Science ®Google Scholar
• Solazzo SA, Ahmed M, Schor-Bardach R, et al. Liposomal doxorubicin increases radiofrequency ablation-induced tumor destruction by increasing cellular oxidative and nitrative stress and accelerating apoptotic pathways. Radiology. 2010;255(1):62–74.
   PubMed Web of Science ®Google Scholar
• Ryan ER, Sofocleous CT, Schöder H, et al. Split-dose technique for FDG PET/CT-guided percutaneous ablation: a method to facilitate lesion targeting and to provide immediate assessment of treatment effectiveness. Radiology. 2013;268(1):288–295.
   PubMed Web of Science ®Google Scholar
• Erinjeri JP, Thomas CT, Samoilia A, et al. Image-guided thermal ablation of tumors increases the plasma level of interleukin-6 and interleukin-10. J Vasc Interv Radiol. 2013;24(8):1105–1112.
   PubMed Web of Science ®Google Scholar
• Ni Y, Ye X, Wan C, et al. Percutaneous microwave ablation (MWA) increased the serum levels of VEGF and MMP-9 in Stage I non-small cell lung cancer (NSCLC). Int J Hyperthermia. 2017;33:1–5.
   PubMed Web of Science ®Google Scholar
• Guan HT, Wang J, Yang M, et al. Changes in immunological function after treatment with transarterial chemoembolization plus radiofrequency ablation in hepatocellular carcinoma patients. China Med J. 2013;126(19):3651–3655.
   PubMed Web of Science ®Google Scholar
• Takaki H, Imai N, Thomas CT, et al. Changes in peripheral blood T-cell balance after percutaneous tumor ablation. Minim Invasive Ther Allied Technol. 2017;26(6):331–337.
   PubMed Web of Science ®Google Scholar
• Finkelstein DM, Ettinger DS, Ruckdeschel JC. Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol. 1986;4(5):702–709.
   PubMed Web of Science ®Google Scholar